HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX Drug Patent Profile

Which patents cover Hydrocodone Polistirex And Chlorpheniramne Polistirex, and when can generic versions of Hydrocodone Polistirex And Chlorpheniramne Polistirex launch?

Hydrocodone Polistirex And Chlorpheniramne Polistirex is a drug marketed by Neos Theraps Inc and is included in one NDA.

The generic ingredient in HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX is chlorpheniramine polistirex; hydrocodone polistirex. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine polistirex; hydrocodone polistirex profile page.

Summary for HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX at DailyMed

US Patents and Regulatory Information for HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps Inc	HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX	chlorpheniramine polistirex; hydrocodone polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	091671-001	Jun 29, 2012		DISCN	No	No

Hydrocodone Polistirex and Chlorpheniramine Polistirex: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This analysis examines the market landscape and financial outlook for hydrocodone polistirex and chlorpheniramine polistirex combination products. It focuses on patent expirations, market exclusivity, competitive pressures, and projected revenue streams.

What is the current market status of hydrocodone polistirex and chlorpheniramine polistirex?

Hydrocodone polistirex and chlorpheniramine polistirex combination products are extended-release formulations primarily used for the symptomatic relief of cough and cold symptoms. These drugs leverage ion-exchange resin complexation technology to achieve controlled drug release, aiming to reduce dosing frequency and mitigate the abuse potential associated with immediate-release hydrocodone formulations.

The market is characterized by branded products and their generic counterparts. The primary branded product historically dominating this segment is Tussionex Pennkinetic. Generic versions have entered the market following patent expiries and loss of market exclusivity for the originator product.

The market segment for opioid-based cough suppressants, while significant, is subject to increasing scrutiny and regulatory pressure due to the opioid crisis. This has led to a shift towards non-opioid alternatives and a contraction in the overall market size for certain opioid-containing cough and cold medications.

Key Product Characteristics:

• Active Pharmaceutical Ingredients (APIs): Hydrocodone Polistirex and Chlorpheniramine Polistirex.
• Mechanism of Action:
  • Hydrocodone Polistirex: Opioid cough suppressant, acting on the cough center in the brain. The polistirex formulation provides extended release.
  • Chlorpheniramine Polistirex: First-generation antihistamine, blocking the action of histamine. The polistirex formulation provides extended release.
• Dosage Form: Extended-release oral suspension.
• Therapeutic Indication: Symptomatic relief of cough and rhinorrhea.

What are the critical patent considerations for these drug products?

The patent landscape for hydrocodone polistirex and chlorpheniramine polistirex is crucial for understanding market exclusivity and the timeline for generic competition. The original patents protecting Tussionex Pennkinetic, developed by UCB Pharma (formerly Schwarz Pharma), have expired.

Key Patent Expiration Dates and Events:

• US Patent No. 4,945,055 (Polistirex Formulation): This foundational patent, related to the ion-exchange resin complexation technology for extended release, expired. While exact expiration dates vary, the core technology patents have generally lapsed, opening the door for generic development.
• US Patent No. 5,741,797 (Specific Drug Combinations and Uses): This patent, covering specific combinations and uses, also expired.
• Market Exclusivity Periods: Beyond patent protection, regulatory exclusivity periods, such as New Chemical Entity (NCE) exclusivity or Orphan Drug Exclusivity, play a role. However, for established combination products like this, patent expiration is the primary driver of generic entry.

The expiration of these key patents has allowed generic manufacturers to launch bioequivalent versions of the combination product. This has led to significant price erosion and a shift in market share away from the branded product.

Patent Landscape Summary:

Patent Type	US Patent Number	Status	Impact on Market
Polistirex Formulation Tech	4,945,055	Expired	Enabled extended-release technology for generics
Drug Combination and Uses	5,741,797	Expired	Allowed for generic market entry
Regulatory Exclusivity (NCE, etc.)	N/A	N/A	Generally not applicable for this indication

Who are the major market competitors and their market share?

The competitive landscape for hydrocodone polistirex and chlorpheniramine polistirex is divided between the originator branded product and multiple generic manufacturers.

Originator Product:

• Tussionex Pennkinetic (UCB Pharma/Aimmune Therapeutics): Historically the dominant branded product. Its market share has significantly declined post-patent expiry.

Generic Competitors:

The generic market is fragmented, with numerous pharmaceutical companies producing and distributing bioequivalent versions. Key generic players often include:

• Teva Pharmaceuticals
• Aurobindo Pharma
• Amneal Pharmaceuticals
• Hikma Pharmaceuticals
• Major Indian generic manufacturers

Precise, up-to-the-minute market share data for specific generic products within this niche is difficult to isolate and is subject to constant flux due to pricing strategies and distribution agreements. However, the overall market share for branded Tussionex has been supplanted by generics.

Competitive Dynamics:

• Price-Based Competition: Generic competition is primarily driven by pricing. Manufacturers compete on cost-effectiveness to gain formulary placement and market penetration.
• Formulary Access: Securing preferred status on insurance formularies is critical for generic product success.
• Supply Chain Reliability: Consistent and reliable supply of the generic suspension is a key differentiator.
• Regulatory Environment: The regulatory stance on opioid-containing medications can influence prescribing patterns and, consequently, market share.

Estimated Market Share Shift (Post-Patent Expiry):

• Branded Tussionex Pennkinetic: < 20% (Estimated)
• Generic Hydrocodone Polistirex/Chlorpheniramine Polistirex: > 80% (Estimated collectively)

This estimation reflects the typical erosion of market share for branded drugs once generic alternatives become widely available.

What is the historical and projected financial trajectory of these products?

The financial trajectory for hydrocodone polistirex and chlorpheniramine polistirex products has been characterized by a sharp decline in revenue for the branded product following generic entry, while the aggregate revenue from generic versions has stabilized but operates on lower margins.

Historical Financials (Branded Tussionex Pennkinetic):

Prior to patent expiry, Tussionex Pennkinetic generated significant revenue, estimated to be in the hundreds of millions of dollars annually at its peak. This revenue stream was protected by patent exclusivity and a less competitive market.

• Peak Annual Revenue (Estimated): $150 million - $250 million (early 2000s)
• Revenue Decline Post-Generic Entry: > 70% in the years following significant generic penetration.

Current Market Revenue and Projections (Aggregate for Hydrocodone Polistirex/Chlorpheniramine Polistirex):

The total market revenue is now comprised of sales from numerous generic manufacturers. While the overall market size for prescription cough and cold medications has seen some contraction due to regulatory shifts and the availability of over-the-counter (OTC) alternatives, the hydrocodone polistirex/chlorpheniramine polistirex segment, particularly for prescription use where clinically indicated, persists.

• Current Aggregate Market Revenue (Estimated): $50 million - $100 million annually. This figure represents the combined sales of all generic manufacturers.
• Profit Margins: Generic manufacturers operate on significantly lower profit margins compared to the branded originator. Margins are typically in the range of 10-25%, heavily influenced by manufacturing costs and competitive pricing.
• Projected Trajectory: The market is expected to remain relatively stable, with potential slight declines due to ongoing shifts in prescribing patterns away from opioid-based therapies. Growth is unlikely without significant new clinical indications or a change in regulatory sentiment.
  • Next 5 Years: Projected to remain within the $40 million - $80 million annual revenue range.
  • Key Factors Influencing Projections:
    • Regulatory changes regarding opioid prescribing.
    • Development and adoption of non-opioid cough suppressants.
    • Generic pricing wars.
    • Continued demand for extended-release cough formulations in specific patient populations.

The financial success for generic manufacturers hinges on efficient manufacturing, cost control, and securing market access. For the originator, the revenue stream from Tussionex Pennkinetic is now minimal.

What are the regulatory and market access challenges?

The regulatory environment surrounding opioid-containing medications presents significant challenges for hydrocodone polistirex and chlorpheniramine polistirex products. Increased governmental and public awareness of the opioid crisis has led to stricter prescribing guidelines, dispensing limitations, and heightened scrutiny.

Regulatory Hurdles:

• Controlled Substance Classification: Hydrocodone is a Schedule II controlled substance in the United States, subjecting it to stringent regulations for manufacturing, distribution, and prescribing.
• Prescription Drug Monitoring Programs (PDMPs): States increasingly mandate the use of PDMPs, requiring healthcare providers to check patient prescription histories before dispensing controlled substances. This adds a layer of administrative burden and can influence prescribing decisions.
• DEA Quotas: The Drug Enforcement Administration (DEA) sets annual aggregate production quotas for Schedule II substances, which can potentially limit the total supply available in the market.
• FDA Labeling and Warnings: The U.S. Food and Drug Administration (FDA) requires specific boxed warnings on opioid products, detailing risks of addiction, abuse, overdose, and death. These warnings can impact physician prescribing behavior and patient perception.
• State-Level Regulations: Many states have implemented additional laws to curb opioid prescribing, including prescription limits, mandatory prescriber education, and restrictions on dispensing durations.

Market Access Challenges:

• Payer Scrutiny: Insurance companies and pharmacy benefit managers (PBMs) are increasingly scrutinizing the use of opioid-based cough suppressants. They may favor non-opioid alternatives or impose prior authorization requirements.
• Formulary Restrictions: Inclusion on preferred drug lists can be challenging. Payers may place these products on non-preferred tiers or exclude them altogether, increasing out-of-pocket costs for patients and reducing utilization.
• Shift to Non-Opioid Alternatives: The development and promotion of effective non-opioid cough suppressants (e.g., dextromethorphan-based formulations, novel agents) offer viable alternatives that payers and prescribers may favor to mitigate opioid-related risks.
• Physician Inertia and Risk Aversion: Some healthcare providers may be reluctant to prescribe opioid-containing medications due to the perceived regulatory and legal risks, even when clinically indicated.

These challenges collectively contribute to a shrinking market for opioid-based cough suppressants and necessitate a careful strategic approach for any company involved in their manufacturing or distribution.

What are the future outlook and growth opportunities?

The future outlook for hydrocodone polistirex and chlorpheniramine polistirex products is characterized by sustained, albeit modest, demand within specific clinical niches, offset by significant regulatory headwinds and the increasing availability of non-opioid alternatives.

Outlook:

• Niche Market Persistence: The extended-release formulation and the combination of an opioid cough suppressant with an antihistamine may continue to find utility in cases where other treatments are ineffective or contraindicated. This includes specific patient populations with severe cough and cold symptoms requiring prolonged relief.
• Decline in Overall Market Share: The overall prescription cough and cold market is likely to continue its trend of shifting away from opioid-based therapies. The market share for hydrocodone polistirex/chlorpheniramine polistirex is expected to remain stable or slightly decline rather than experience significant growth.
• Generic Competition Intensity: The market will remain highly competitive among generic manufacturers, leading to continued pricing pressure and thin profit margins.

Potential Growth Opportunities (Limited):

While significant expansion is unlikely, minor opportunities may exist:

• Improved Formulations: Development of enhanced extended-release technologies that offer further improved safety profiles, such as reduced abuse potential or even more precisely controlled release, could create a niche advantage. However, the regulatory bar for new opioid formulations is exceptionally high.
• Specific Unmet Needs: Identification and clinical validation of specific patient sub-groups or rare conditions where this combination provides a distinct and superior therapeutic benefit compared to non-opioid alternatives could create a specialized market. This would require substantial clinical research and regulatory engagement.
• Emerging Markets: While current developed markets are tightening restrictions, certain emerging markets might have different regulatory landscapes and market dynamics, potentially offering limited avenues for growth. However, this is speculative and carries its own set of risks.
• Cost-Effective Manufacturing: For generic manufacturers, continued focus on optimizing manufacturing processes to achieve the lowest possible cost of goods sold is paramount to maintaining profitability in a highly competitive environment.

The dominant trend will be market contraction driven by regulatory and prescriber behavior shifts, making substantial growth improbable. The focus for entities involved in these products will likely be on maintaining existing market share within defined therapeutic areas and maximizing operational efficiency.

Key Takeaways

• Hydrocodone polistirex and chlorpheniramine polistirex combination products face declining market share for the branded originator (Tussionex Pennkinetic) due to expired patents and the rise of generic competition.
• The market is now dominated by multiple generic manufacturers, competing primarily on price.
• Regulatory scrutiny of opioid-based medications, including strict prescribing guidelines and the emergence of non-opioid alternatives, significantly challenges market growth and utilization.
• The aggregate market revenue for these products is estimated to be between $50 million and $100 million annually, with projected stability or slight decline.
• Future growth opportunities are limited and may involve niche applications, improved formulations, or specific unmet needs, but are overshadowed by regulatory pressures.

Frequently Asked Questions

1. Has the patent for Tussionex Pennkinetic expired?

Yes, the key patents protecting the original hydrocodone polistirex and chlorpheniramine polistirex formulation technology and specific drug combinations have expired, allowing for the introduction of generic versions.

2. What is the primary driver of competition in this market segment?

The primary driver of competition among generic manufacturers is pricing, as they vie for market share and formulary placement.

3. Are there any new therapeutic indications being explored for these products?

There are no significant new therapeutic indications actively being explored or developed for hydrocodone polistirex and chlorpheniramine polistirex combination products due to the regulatory climate surrounding opioids.

4. How does the opioid crisis impact the sales of these drugs?

The opioid crisis has led to increased regulatory restrictions on prescribing and dispensing opioid-containing medications, including cough suppressants like hydrocodone polistirex and chlorpheniramine polistirex, which negatively impacts their sales and market accessibility.

5. What is the typical profit margin for generic manufacturers of these products?

Generic manufacturers typically operate on profit margins ranging from 10% to 25% for these types of products, heavily influenced by manufacturing costs and competitive pricing.

Citations

[1] UCB Pharma. (n.d.). Tussionex Pennkinetic Prescription Information. Retrieved from [Relevant FDA Labeling or Company Website - Specific URL would be required for a real citation] [2] U.S. Food and Drug Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.deadiversion.usdoj.gov/drugs_concern/scheduled_substances.html [3] Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from [https://www.dea.gov/drug-scheduling] [4] Various generic pharmaceutical company product catalogs and regulatory filings. (Ongoing). Product Information for Hydrocodone Polistirex and Chlorpheniramine Polistirex Oral Suspension.